Pascal Soriot is stuck in a Chinese limbo. In recent months, the CEO of $205 billion drug giant AstraZeneca has seen his ...

At 24 months, endocrine therapy appeared to have a more negative effect on HRQOL as measured by the global health status (GHS ...

The AstraZeneca PLC ADR AZN dropped 0.54% to $66.58 Friday, on what proved to be an all-around mixed trading session for the ...

AstraZeneca PLC AZN shares inched down 0.95% to £104.68 Friday, on what proved to be an all-around grim trading session for ...

Action is the latest following Baldwin’s investigation into the extremely high prices these companies charge for inhalers ...

AstraZeneca (AZN) and Merck (MRK) reported positive long-term survival data for their drug Lynparza in the treatment of ...

AstraZeneca is proud to announce the successful conclusion of its inaugural Week of Service, which took place across the ...

In a report released on December 11, David Evans from Kepler Capital maintained a Hold rating on AstraZeneca (AZN – Research Report), with a ...

Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has ...

The AstraZeneca share price is down almost 20% since September! What’s behind this drop, and where do analysts think the ...

Americans with asthma and 16 million Americans with COPD need inhalers to breathe. Vermont Business Magazine Sen. Bernie Sanders (I-Vermont), Chairman of the Senate Com ...

AstraZeneca and Merck report Lynparza's significant survival benefits in high-risk breast cancer and Keytruda combo results ...